Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan

INTRODUCTION: Teneligliptin, a dipeptidyl peptidase 4 inhibitor, was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan in 2012. However, clinical trials of teneligliptin involved limited numbers of elderly patients. Therefore, we investigated the safety and efficacy of teneligli...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Takashi, Haneda, Masakazu, Ito, Hiroshi, Sasaki, Kazuyo, Yamada, Yuka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467469/
https://www.ncbi.nlm.nih.gov/pubmed/32323194
http://dx.doi.org/10.1007/s12325-020-01306-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467469/
https://www.ncbi.nlm.nih.gov/pubmed/32323194
http://dx.doi.org/10.1007/s12325-020-01306-0

Ejemplares similares